Advances in targeted therapy for unresectable melanoma: New drugs and combinations
- 1 April 2015
- journal article
- review article
- Published by Elsevier BV in Cancer Letters
- Vol. 359 (1), 1-8
- https://doi.org/10.1016/j.canlet.2014.12.050
Abstract
No abstract availableKeywords
Funding Information
- National Nature Science Foundation of China (81372872, 81402215, 81320108022)
- University Cancer Foundation
This publication has 58 references indexed in Scilit:
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised studyThe Lancet Oncology, 2013
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyThe Lancet Oncology, 2013
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorJournal of Clinical Oncology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early HypertensionPLOS ONE, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Nilotinib in patients with metastatic melanoma harboring KIT gene aberrationInvestigational New Drugs, 2011
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or AmplificationJournal of Clinical Oncology, 2011
- A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue CorrelatesPLOS ONE, 2010